Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End‐Stage Kidney Disease

Chih‐Yuan Niu,Shang‐Feng Yang,Shuo‐Ming Ou,Cheng‐Hsueh Wu,Po‐Hsun Huang,Chung‐Lieh Hung,Chih‐Ching Lin,Szu‐Yuan Li

DOI: https://doi.org/10.1161/JAHA.122.026407

2022-09-06

Abstract:Background Heart failure with reduced ejection fraction (HFrEF) is a chronic disease with substantial mortality. Management of HFrEF has seen significant breakthrough after the launch of neprilysin inhibitor. The PARADIGM‐HF (Prospective Comparison of ARNI with ACEI to Determine Impacton Global Mortality and Morbidity in Heart Failure) trial showed that sacubitril/valsartan significantly reduces HFrEF mortality and the heart failure hospitalization rate. However, in patients with advanced kidney disease, who have the highest prevalence of heart failure, the efficacy and safety of sacubitril/valsartan remains uncertain. We aim to study the efficiency of sacubitril/valsartan in patients with end‐stage kidney disease. Methods and Results Heart function was screened by echocardiogram among all patients with end‐stage kidney disease in 2 hospitals. Patients with HFrEF received either sacubitril/valsartan or conventional treatment. Fifteen echocardiographic parameters were compared before and after treatment. After 1‐year sacubitril/valsartan treatment, parameters of systolic (left ventricular ejection fraction 31.3% to 45.1%, P <0.0001; left ventricular end‐systolic volume 95.7 to 70.1 mL, P =0.006; left ventricular internal diameter at end‐systole phase 47.2 to 40.1 mm, P =0.005), and diastolic (E/A ratio 1.3 to 0.8, P =0.009; E/Med e' ratio 25.3 to 18.8, P =0.010) function improved in patients with HFrEF and end‐stage kidney disease. These parameters were unchanged in the conventional treatment group. Serum potassium did not increase in the sacubitril/valsartan group. Conclusions Sacubitril/valsartan improves left ventricular systolic and diastolic function in patients with HFrEF and end‐stage kidney disease. Nonstandard Abbreviations and Acronyms ARNI angiotensin receptor II blocker‐neprilysin inhibitor HFrEF heart failure with reduced ejection fraction Clinical Perspective What Is New? Clinical trials showed sacubitril/valsartan has benefit effect in heart failure with reduced ejection fraction, but these trials excluded patients with an estimated glomerular filtration rate of <30 mL/min. The treatment of heart failure in patients with end‐stage kidney disease therefore is largely unknown. The authors used 15 echocardiogram parameters to investigate sacubitril/valsartan therapeutic effect in patients with end‐stage kidney disease and heart failure with reduced ejection fraction; they found that 1‐year of treatment with sacubitril/valsartan significantly improves systolic and diastolic heart function in these patients. Sacubitril/valsartan does not increase hyperkalemia or hypotension risk in patients with end‐stage kidney disease. What Are the Clinical Implications? Sacubitril/valsartan improves left ventricular systolic and diastolic function in patients with end‐stage kidney disease. This result fulfills the unmet need of heart failure treatment in advanced chronic kidney disease and opens a window of opportunity for patients with end‐stage kidney disease who have heart failure with reduced ejection fraction. Congestive heart failure affects 40 million people worldwide, 1 accounting for 2% of the global adult population. 2 The diagnosis is usually based on clinical symptoms, including shortness of breath, leg swelling, excessive tiredness, and pulmonary congestion. 2 , 3 , 4 Reduced cardiac output is generally accompanied by structural and functional abnormality of the heart, which disrupts its ejection of blood in systolic phase or refilling during the diastolic phase. 5 , 6 , 7 Based on whether the ability of the left ventricle to contract or to relax is affected, heart failure is divided into 2 types: heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction. 8 Patients with HFrEF, defined as ejection fraction <40%, 9 carry a very high morbidity and mortality rate. 10 , 11 , 12 Large‐scale epidemiology studies showed the survival rates of patients with HFrEF are even worse than tho -Abstract Truncated-